RE:RE:RE:RE:RE:RE:The number to beat is 39%CR...(for now).999: It's not too hard to conjure up complex sounding projections. Part of my work involves working with data analysts but must admit I'm not one. One thing though, we don't know what percent of the total patient population for BCGR-NMIBC will pick Ruvidar. Marketing dollars can sway votes where it matters. GBM validity is still many many years out. So is NSCLC, given that activation of Ruvidar still needs to be perfected . I'd be happy to see a $1.5B MC, which is about $5 US. Till that point, talk to us about where you see the next million dollars coming from to continue our current journey.
99942Apophis wrote: N0taP00p wrote: It's easier now to see why many here are so wound up and unable to have rational conversations. It is much easier to dream up and project 20,000% to 30,000% gains and then protect that balloon from being popped by real questions around finances and timelines, for example. When we get to $5, let's talk. We'll have a happy starting point.
99942Apophis wrote: That 40B would be for the perfect dream of NMIBC, MIBC, vaccine, GBM & NSCLC giving us a share price of $125.00, realistically a $40 to $60 range isn't out of the question. I know some of my fellow posters might roll their eyes but this is highly possible!
You've got a deal NOtaPOOp, run the North American numbers yourself X whichever treatment charge you wish minus average cost of sales and partnership percentage then with the remaining figure reduce it by an estimated tax. Firstly though don't forget to take a low first year percentage of patients then calculate a reasonable increase of patients for say the first 5 years which should take you to at least 60% of total patients.
Worldwide numbers could be merge into revenue slow at first but building higher also with each year, so you decide if worldwide revenue comes in 2nd, 3rd or 4th year after N.America. Since this will be a new growth stock a suggested PE Ratio should be between 50 and 150.
These numbers could belong to Theralase or the one that buys them out, enjoy.